News | April 15, 2026
Vetter ramps up global clinical manufacturing push with major US & Europe expansion
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The approval was driven by data from the Phase III TULIP-SC trial
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Subscribe To Our Newsletter & Stay Updated
